Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
AVDL Stock | USD 8.00 0.33 3.96% |
About 58% of all Avadel Pharmaceuticals' institutional investors are looking to take a long position. The analysis of overall sentiment of trading Avadel Pharmaceuticals PLC stock suggests that some investors are interested at this time. Avadel Pharmaceuticals' investing sentiment shows overall attitude of investors towards Avadel Pharmaceuticals PLC.
Avadel |
-- Approximately 50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150 percent increase over 19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of 240 260 million in 2025, representing 50 percent year-over-year growth at the midpoint -- -- Management to host a conference call today at 430 p.m. ET -- DUBLI
Read at finance.yahoo.com
![]() |
Avadel Pharmaceuticals Current Investor Sentiment
Comfort Level 58
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Avadel Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Avadel Pharmaceuticals PLC.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentAcquiring |
Avadel Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Avadel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avadel Pharmaceuticals Historical Investor Sentiment
Investor biases related to Avadel Pharmaceuticals' public news can be used to forecast risks associated with an investment in Avadel. The trend in average sentiment can be used to explain how an investor holding Avadel can time the market purely based on public headlines and social activities around Avadel Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Avadel Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Avadel Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Avadel Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Avadel Pharmaceuticals.
Avadel Pharmaceuticals Fundamental Analysis
We analyze Avadel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avadel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avadel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Avadel Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Avadel Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avadel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Avadel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Avadel Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Avadel Pharmaceuticals Related Equities
LFCR | Lifecore Biomedical | 1.83 | ||||
ASRT | Assertio Therapeutics | 1.25 | ||||
ANIP | ANI Pharmaceuticals | 0.64 | ||||
ITCI | Intracellular | 0.07 | ||||
AMRX | Amneal Pharmaceuticals, | 0.13 | ||||
ALKS | Alkermes Plc | 0.25 | ||||
DVAX | Dynavax Technologies | 0.38 | ||||
NBIX | Neurocrine Biosciences | 0.46 | ||||
EVOK | Evoke Pharma | 0.82 | ||||
AQST | Aquestive Therapeutics | 2.27 | ||||
DERM | Journey Medical | 5.30 | ||||
IRWD | Ironwood Pharmaceuticals | 8.06 |
Check out Avadel Pharmaceuticals Hype Analysis, Avadel Pharmaceuticals Correlation and Avadel Pharmaceuticals Performance. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share | Quarterly Revenue Growth 26.743 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.